Abstract:Simple Summary Squamous cell carcinoma (SCC) is the most prevalent type of human cancer worldwide and represents the majority of head and neck tumors. As SCC from aerodigestive or genitourinary tracts share not only common etiology and histological features but also molecular patterns, the major objectives of this study were the establishment of a pan-SCC-related prognostic gene signature by an integrative analysis of multi-omics data and the elucidation of underlying oncogenic pathway activities as potential vulnerabilities for a more efficient and less toxic therapy. Our approach delivers a reliable molecular classifier to identify HNSCC and other SCC patients at higher risk for treatment failure with tumors characterized by a more prominent MAPK activity, who might benefit from a targeted treatment with MEK inhibitors. Squamous cell carcinoma (SCC) is the most prevalent histological type of human cancer, including head and neck squamous cell carcinoma (HNSCC). However, reliable prognostic gene signatures for SCC and underlying genetic and/or epigenetic principles are still unclear. We identified 37 prognostic candidate genes by best cutoff computation based on survival in a pan-SCC cohort (n = 1334) of The Cancer Genome Atlas (TCGA), whose expression stratified not only the pan-SCC cohort but also independent HNSCC validation cohorts into three distinct prognostic subgroups. The most relevant prognostic genes were prioritized by a Least Absolute Shrinkage and Selection Operator Cox regression model and were used to identify subgroups with high or low risks for unfavorable survival. An integrative analysis of multi-omics data identified FN1, SEMA3A, CDH2, FBN1, COL5A1, and ADAM12 as key nodes in a regulatory network related to the prognostic phenotype. An in-silico drug screen predicted two MEK inhibitors (Trametinib and Selumetinib) as effective compounds for high-risk SCC based on the Cancer Cell Line Encyclopedia, which is supported by a higher p-MEK1/2 immunohistochemical staining of high-risk HNSCC. In conclusion, our data identified a molecular classifier for high-risk HNSCC as well as other SCC patients, who might benefit from treatment with MEK inhibitors.

Supplementary Tables S1-S8 from Targeting the c-Met/FZD8 Signaling Axis Eliminates Patient-Derived Cancer Stem–like Cells in Head and Neck Squamous Carcinomas

Supplementary Figures S1-S15 from Targeting the C-Met/fzd8 Signaling Axis Eliminates Patient-Derived Cancer Stem–like Cells in Head and Neck Squamous Carcinomas

Identification of Cancer Stem Cells in Human Gastrointestinal Carcinoid and Neuroendocrine Tumors.

Targeting the C-Met/fzd8 Signaling Axis Eliminates Patient-Derived Cancer Stem-Like Cells in Head and Neck Squamous Carcinomas.

Biomarkers Of Head And Neck Cancer Stem Cells And Targeted Therapeutic Strategies

Supplementary Methods and References from Targeting the C-Met/fzd8 Signaling Axis Eliminates Patient-Derived Cancer Stem–like Cells in Head and Neck Squamous Carcinomas

C-Met pathway promotes self-renewal and tumorigenecity of head and neck squamous cell carcinoma stem-like cell

Role of C-Met in the Progression of Human Oral Squamous Cell Carcinoma and Its Potential As a Therapeutic Target.

Prognostic Gene Signature for Squamous Cell Carcinoma with a Higher Risk for Treatment Failure and Accelerated MEK-ERK Pathway Activity

Understanding metastatic SCCHN cells from unique genotypes to phenotypes with the aid of an animal model and DNA microarray analysis

Single-Cell Molecular Profiling of Head and Neck Squamous Cell Carcinoma Reveals Five Dysregulated Signaling Pathways Associated With Circulating Tumor Cells

Supplementary Tables 1-2 and Supplementary Figures S1-S5 and Legends from Suppression of the Growth and Invasion of Human Head and Neck Squamous Cell Carcinomas Via Regulating STAT3 Signaling and the Mir-21/Β-catenin Axis with HJC0152

Head Neck Squamous Cell Carcinoma C‐met+ Cells Display Cancer Stem Cell Properties and Are Responsible for Cisplatin‐resistance and Metastasis

The molecular markers of cancer stem cells in head and neck tumors

Cancer stem cell biomarkers for head and neck squamous cell carcinoma: A bioinformatic analysis.

Supplementary Table 1 from CD47-SIRPα Blockade Sensitizes Head and Neck Squamous Cell Carcinoma to Cetuximab by Enhancing Macrophage Adhesion to Cancer Cells

Identification of tumor stemness and immunity related prognostic factors and sensitive drugs in head and neck squamous cell carcinoma

Analysis of the Prognosis and Therapeutic Value of the CXC Chemokine Family in Head and Neck Squamous Cell Carcinoma

Validation of Gene Profiles for Analysis of Regional Lymphatic Metastases in Head and Neck Squamous Cell Carcinoma

Inhibition Of Src Family Kinases Reduces Myeloid-Derived Suppressor Cells In Head And Neck Cancer

5T4-Targeted Therapy Ablates Cancer Stem Cells and Prevents Recurrence of Head and Neck Squamous Cell Carcinoma